Zevra Therapeutics, Inc. (ZVRA) Debt by Year
Zevra Therapeutics, Inc. carried $61.9M in long-term debt against $62.4M in cash and equivalents at the end of fiscal year 2025. This represents an increase of 4.1% from the prior fiscal year. The table below carries 13 fiscal years, from 2013 to 2025, and the quarters Zevra Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ZVRA Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $61.9M+4.1% | $59.5M+1074.6% | $5.1M | N/A | N/A | $67.7M-12.5% | $77.3M-5.0% | $81.4M-12.2% | $92.7M | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $62.4M+84.7% | $33.8M-21.5% | $43.0M-34.2% | $65.5M-41.7% | $112.3M+2566.7% | $4.2M+31.0% | $3.2M-82.5% | $18.4M+69.3% | $10.9M-35.1% | $16.8M-48.1% | $32.3M+215.1% | $10.3M+420.8% | $2.0M |
ZVRA Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0-100.0% | $0-100.0% | $61.9M+4.1% | $61.3M+4.1% | $60.7M+4.1% | $60.1M | $59.5M+1074.6% | $58.9M | $58.3M | N/A | $5.1M | N/A |
| Cash & Equivalents | $145.3M+204.6% | $95.6M+156.0% | $62.4M+84.7% | $54.4M+0.7% | $47.7M+21.5% | $37.3M-12.9% | $33.8M-21.5% | $54.0M+24.9% | $39.3M-40.7% | $42.8M+6.6% | $43.0M-34.2% | $43.3M-38.2% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Zevra Therapeutics, Inc. financials
Frequently Asked Questions
What was Zevra Therapeutics, Inc.'s long-term debt in fiscal year 2025?
Zevra Therapeutics, Inc. carried $61.9M in long-term debt against $62.4M in cash and equivalents at the end of fiscal year 2025.
How fast is Zevra Therapeutics, Inc.'s long-term debt growing?
Zevra Therapeutics, Inc. (ZVRA) long-term debt rose by 4.1% year over year, from $59.5M to $61.9M in fiscal year 2025.
What was Zevra Therapeutics, Inc.'s long-term debt in the most recent quarter?
Zevra Therapeutics, Inc. (ZVRA) reported $0 in long-term debt in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Zevra Therapeutics, Inc. (ZVRA) reported on that line in every period on record.